These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30480087)

  • 1. 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease.
    Cruse B; Morales-Briceño H; Chang FCF; Mahant N; Ha AD; Kim SD; Wolfe N; Kwan V; Tsui DS; Griffith JM; Galea D; Fung VSC
    NPJ Parkinsons Dis; 2018; 4():34. PubMed ID: 30480087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
    Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Freire-Alvarez E; Kurča E; Lopez Manzanares L; Pekkonen E; Spanaki C; Vanni P; Liu Y; Sánchez-Soliño O; Barbato LM
    Mov Disord; 2021 Nov; 36(11):2615-2623. PubMed ID: 34236101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
    Chaudhuri KR; Antonini A; Pahwa R; Odin P; Titova N; Thakkar S; Snedecor SJ; Hegde S; Alobaidi A; Parra JC; Zadikoff C; Bergmann L; Standaert DG
    J Parkinsons Dis; 2022; 12(7):2071-2083. PubMed ID: 35964203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia.
    Fabbri M; Zibetti M; Calandra-Buonaura G; Contin M; Sambati L; Mohamed S; Romagnolo A; Berchialla P; Imbalzano G; Giannini G; Rizzone MG; Artusi CA; Cortelli P; Lopiano L
    Mov Disord Clin Pract; 2020 Nov; 7(8):930-939. PubMed ID: 33163564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ
    Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Wang L; Li J; Chen J
    Front Neurol; 2018; 9():620. PubMed ID: 30104997
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What can we learn from the effect of trihexyphenidyl on motor fluctuations during continuous levodopa-carbidopa intestinal gel infusion (LCIG)? - First documented case.
    Kubo SI; Nakamura K; Tada Y; Kashio N; Yamashita S
    Clin Park Relat Disord; 2020; 3():100071. PubMed ID: 34316650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa-Carbidopa Intestinal Gel for Parkinson's Disease over 11 years: One Center's "Real-World" Experience.
    Vekhande C; Hamed M; Tremain G; Mah J; Shetty A; Lazarescu A; Suchowersky O
    Can J Neurol Sci; 2023 Jul; ():1-8. PubMed ID: 37462070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.